A 73-year-old male patient presented with unresectable advanced esophageal cancer and metastases in the left axillary, the thoracic and the paraaortic lymph nodes, which were treated with docetaxel/nedaplatin (CDGP)/5-fluorouracil (5-FU) therapy. CDGP was administered in multiple divided doses, because the patient exhibited decreased renal function. One cycle of chemotherapy consisted of CDGP (20 mg/body/day) and 5-FU (750 mg/body/day) from days 1 to 5, docetaxel (60 mg/body) on day 1, followed by a three-week interval. The patient underwent four cycles of chemotherapy. Upper gastrointestinal endoscopy was performed after the completion of the third cycle, when the patient exhibited no evidence of a primary tumor, and no cancer cells were detected via biopsy. The efficacy of the chemotherapy was maintained after the fourth cycle, indicating a complete response(CR). Computed tomography was performed after the first cycle and showed a reduction of the primary tumor(CR) and lymph node metastases. After the fourth cycle, enlarged lymph nodes were remarkably reduced, which was assessed as a partial response(PR). The reported adverse events were Grade 1 pyrexia, Grade 3 diarrhea and Grade 2 leukopenia. Therefore, docetaxel/CDGP/5-FU therapy is a promising regimen for advanced esophageal cancer in association with a lower incidence of nephrotoxicity and hepatotoxicity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.